Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05427812 · ClinicalTrials.gov registry record · Phase 1
Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma
A Phase 1 study, sponsored by Ichnos Sciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT05427812 is a Phase 1 study that was terminated before completion, run by Ichnos Sciences. The registered enrollment target is 29 participants.
The verdict
NCT05427812, a Phase 1 study, was terminated before completion, sponsored by Ichnos Sciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
This study is a first-in-human, Phase 1/2, open label study that will evaluate safety and efficacy of ISB 1442 in relapsed/refractory multiple myeloma (R/R MM).
Interventions
- DRUG ISB 1442 SC injection escalating doses
- DRUG ISB 1442 SC injection at RP2D
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2022-09-27 |
| Est. Completion | 2024-11-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05427812
The ClinicalTrials.gov registry entry for NCT05427812 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ichnos Sciences, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ISB 1442 SC injection escalating doses is the first listed.
NCT05427812 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05427812 about?
NCT05427812 is a clinical study titled "Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma". This study is a first-in-human, Phase 1/2, open label study that will evaluate safety and efficacy of ISB 1442 in relapsed/refractory multiple myeloma (R/R MM).
What is the current status of trial NCT05427812?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2022-09-27. Estimated completion is 2024-11-19.
What interventions are being tested in trial NCT05427812?
The interventions under investigation include: ISB 1442 SC injection escalating doses (DRUG), ISB 1442 SC injection at RP2D (DRUG).
Who is sponsoring clinical trial NCT05427812?
This trial is sponsored by Ichnos Sciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.